Skip to content
Life Sciences Series B Founded 2010

Cresilon

Developer of hemostatic products for wound care. The company offers VETIGEL Hemostatic Gel(a prescription hemostatic gel kit for animal use only. It can stop moderate to severe bleeds in animals), and TRAUMAGEL a hemostatic device for temporary use to control external traumatic bleeding not amenable to tourniquet application. Founded in 2010, headquartered in New York City, United States. The company has raised…

📍 New York City, United States · Wound Care,

Funding snapshot

Last roundSeries B
Amount$29M
Date24 April 2026
Total raised$142M
Team size92

About

Developer of hemostatic products for wound care. The company offers VETIGEL Hemostatic Gel(a prescription hemostatic gel kit for animal use only. It can stop moderate to severe bleeds in animals), and TRAUMAGEL a hemostatic device for temporary use to control external traumatic bleeding not amenable to tourniquet application. Founded in 2010, headquartered in New York City, United States. The company has raised $142.4M in funding at the series b stage. Cresilon operates in the Wound Care, Nanotechnology sectors. The company focuses on Wound Care, Dressing. Notable investors include Paulson Investment, Valued ventures, Hammerstone Capital, PKJ Ventures, IMEX VP Investment Group, Design Technologies, among others.

Business model

Nanotechnology > Nanoenabled Products > Life Science > Drugs > Wound Care,

Wound Care > Medical Devices > Therapeutic Devices > Dressing and Wound Closure > Dressing

Institutional investors

Paulson Investment Valued ventures Hammerstone Capital PKJ Ventures IMEX VP Investment Group Design Technologies Innovating Capital Dorm Room Fund

Latest coverage

No articles yet.

Raising like Cresilon?

Analyze your pitch deck before your next raise.

Analyze My Deck →